Alx Oncology Holdings (ALXO) Research & Development (2019 - 2026)

Alx Oncology Holdings (ALXO) has 8 years of Research & Development data on file, last reported at $13.6 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 43.04% year-over-year to $13.6 million; the trailing twelve-month figure through Mar 2026 stood at $66.7 million (down 38.54% YoY), and the FY2025 full-year result was $77.0 million, down 33.84% from the prior year.
• Research & Development declined to $13.6 million in Q1 2026, from $17.6 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $45.8 million in Q3 2023 to a low of $13.6 million in Q1 2026.
• A 5-year average of $26.3 million and a median of $25.2 million in 2022 frame the typical range for Research & Development.
• Across the five-year window, Research & Development surged 138.54% in 2022 and plunged 47.99% in 2025, its largest moves.
• Tracing ALXO's Research & Development over 5 years: stood at $25.2 million in 2022, then surged by 65.83% to $41.8 million in 2023, then tumbled by 43.68% to $23.5 million in 2024, then slipped by 25.02% to $17.6 million in 2025, then slipped by 22.89% to $13.6 million in 2026.
• Business Quant data shows ALXO's Research & Development at $13.6 million in Q1 2026, $17.6 million in Q4 2025, and $17.4 million in Q3 2025.